Emily J. Hadgkiss, 1 George A. Jelinek, 1,2 Tracey J. Weiland, 1,3 Naresh G. Pereira, 4 Claudia H. Marck, 1 and Dania M.

Similar documents
WCPT COUNTRY PROFILE December 2017 SWEDEN

WCPT COUNTRY PROFILE December 2017 SERBIA

WCPT COUNTRY PROFILE December 2017 HUNGARY

Q1 What age are you?

World Connections Committee (WCC) Report

Appendix F: Test-Curriculum Matching Analysis

508 the number of suicide deaths in deaths per 100,000 people was the suicide rate in Suicide deaths in 2013 by gender

Terms and Conditions. VISA Global Customer Assistance Services

Main developments in past 24 hours

Smokefree Policies in Europe: Are we there yet?

Appendix F. The Test-Curriculum Matching Analysis Science TIMSS 2011 INTERNATIONAL RESULTS IN SCIENCE APPENDIX F 479

EURO POLIO PAGE Data as of 04 October 2005 (Week 38)

Tobacco: World Markets and Trade

Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG-SAFE)

IOSH No Time to Lose campaign: working together to tackle asbestos-related cancer #NTTLasbestos. Jonathan Hughes IOSH Vice President

Men & Health Work. Difference can make a difference Steve Boorman & Ian Banks RSPH Academy 2013

Global EHS Resource Center

Pharmaceutical, Medical and Health-related Government and Regulatory bodies around the world.

Overview of drug-induced deaths in Europe - What does the data tell us?

Field of Post-M.D. Training

WELLNESS COACHING. Wellness & Personal Fitness Solution Providers

Where we stand in EFORT

Alcohol-related harm in Europe and the WHO policy response

European status report on alcohol and health Leadership, awareness and commitment

Louisville '19 Attachment #69

Drug Prices Report Opioids Retail and wholesale prices * and purity levels,by drug, region and country or territory (prices expressed in US$ )

Allied Health: Sustainable Integrated Health Care for all Australians

Design and Analysis of a Cancer Prevention Trial: Plans and Results. Matthew Somerville 09 November 2009

Sperm donation Oocyte donation. Hong Kong þ Guideline þ þ Hungary þ þ þ þ Israel þ þ þ þ Italy þ þ þ. Germany þ þ þ þ Greece þ þ þ þ

Undetectable = Untransmittable. Mariah Wilberg Communications Specialist

- Network for Excellence in Health Innovation

Country-wise and Item-wise Exports of Animal By Products Value Rs. Lakh Quantity in '000 Unit: Kgs Source: MoC Export Import Data Bank

REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS

European Collaboration on Dementia. Luxembourg, 13 December 2006

Inequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe

MENTAL HEALTH CARE. OECD HCQI Expert meeting 17 th of May, Rie Fujisawa

European Status report on Alcohol and Health

Recommended composition of influenza virus vaccines for use in the 2007 influenza season

WELLNESS COACHING. Wellness & Personal Fitness Solution Providers NZ & Australia

ESPEN Congress Geneva 2014 FOOD: THE FACTOR RESHAPING THE SIZE OF THE PLANET

The health economic landscape of cancer in Europe

The cancer burden in the European Union and the European Region: the current situation and a way forward

Injection Techniques Questionnaire (ITQ) WorldWide Results Needle Gauge

Engagement in language assessment / Regions of Europe

Emerging Risks Mapping of Activities in Member States. 67th Advisory Forum meeting, Utrecht, The Netherlands, 6 February 2018

Cross Border Genetic Testing for Rare Diseases

WHO REGIONAL OFFICE FOR EUROPE RECOMMENDATIONS ON INFLUENZA

Country Length Discount Travel Period Anguilla All 20% off 08/24/11 12/15/11 Antigua All 20% off 08/24/11 12/15/11 Argentina All 20% off 08/24/11

LEBANON. WCPT COUNTRY PROFILE December 2018

CND UNGASS FOLLOW UP

Real Life, Real PD Survey

The Test-Curriculum Matching Analysis: Science

D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells

D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells

Rheumatoid Arthritis Disease Burden and Access to Treatment

RECOMMENDATIONS ON INFLUENZA VACCINATION DURING THE WINTER SEASON

The Current Status of Cardiac Electrophysiology in ESC Member Countries J. Brugada, P. Vardas, C. Wolpert

DENMARK. WCPT COUNTRY PROFILE December 2018

Table 7.1 Summary information for lung cancer in Ireland,

UK bowel cancer care outcomes: A comparison with Europe

Department of Biological Standardisation OMCL Network & Healthcare (DBO)

Media Release. Inaugural study reveals that more than one in four women in European and Central Asian prisons locked up for drug offences

PROMOTION AND PROTECTION OF ALL HUMAN RIGHTS, CIVIL, POLITICAL, ECONOMIC, SOCIAL AND CULTURAL RIGHTS, INCLUDING THE RIGHT TO DEVELOPMENT

A report on the epidemiology of selected vaccine-preventable diseases in the European Region 30% 20% 10%

Yersiniosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods. Epidemiology

NobelDesign 1.3 Installation guide

GERMANY. WCPT COUNTRY PROFILE December 2018

Access to treatment and disease burden

FOURIER STUDY GREYLOCK PRESS: CTS PRODUCT SAMPLE - FOURIER YES. Did the study achieve its main objective?

11 Melanoma of the skin

Palliative nursing care of children and young people across Europe

United Kingdom National External Quality Assessment Service for Microbiology [Established 1971]

Monthly measles and rubella monitoring report

PARALLELISM AND THE LEGITIMACY GAP 1. Appendix A. Country Information

Table 6.1 Summary information for colorectal cancer in Ireland,

Population- based cancer survival estimates

European Community Pharmacy: a reference in Public Health

Drinking guidelines used in the context of early identification and brief interventions in Europe: overview of RARHA survey results

Where do EU Contries set the limit for low risk drinking.

Epidemiology of Legionnaires Disease in Europe Birgitta de Jong on behalf of ELDSNet ESGLI conference 22 September 2016

Burden and cost of alcohol, tobacco and illegal drugs globally and in Europe

TEDDY. Teddy Network of Excellence. Annagrazia ALTAVILLA. Ph.D. Sciences Ethics LL.M. Health Law. diterranée

Injection Techniques Questionnaire (ITQ) WorldWide Results Insulin Usage

Table 9.1 Summary information for stomach cancer in Ireland,

NobelProcera Implant Bar Overdenture EXPERIENCE THE NEW WORLD OF CAD/CAM DENTISTRY

Who is a migrant? 12/10/2018. HIV and migrants. Heterogeneous groups of persons with different migration drivers

MEDIA BACKGROUNDER. Teriflunomide: A novel oral drug being investigated for the treatment of Multiple Sclerosis (MS)

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Prevention of Oral Cancer Special Interest Working Group

THE CARE WE PROMISE FACTS AND FIGURES 2017

Drug resistance TB in People Living with HIV: research questions and priorities.

Overall survival: 1 st line therapy

Highlighting in the WHO European Region:

Transcription:

Neurology Research International Volume 2013, Article ID 129417, 5 pages http://dx.doi.org/10.1155/2013/129417 Erratum Erratum to Methodology of an International Study of People with Multiple Sclerosis Recruited through Web 2.0 Platforms: Demographics, Lifestyle, and Disease Characteristics Emily J. Hadgkiss, 1 George A. Jelinek, 1,2 Tracey J. Weiland, 1,3 Naresh G. Pereira, 4 Claudia H. Marck, 1 and Dania M. van der Meer 1 1 Emergency Practice Innovation Centre, St Vincent s Hospital, Melbourne, VIC 3065, Australia 2 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia 3 Department of Medicine, The University of Melbourne (St Vincent s Hospital), Melbourne, VIC 3065, Australia 4 Faculty of Medicine, The University of Notre Dame Australia, Fremantle, WA 6959, Australia Correspondence should be addressed to Emily J. Hadgkiss; emily.hadgkiss@svhm.org.au Received 7 June 2013; Accepted 18 July 2013 Copyright 2013 Emily J. Hadgkiss et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The authors would like to make a number of corrections. During reidentification of data to allow a scheduled email to participants, a coding anomaly was detected, such that the identification and filtering out of duplicates had been incorrectly undertaken. This meant that some participants were incorrectly removed from the dataset prior to analysis while some duplicate entries had been included in analysis. Many minor changes to the results in the published paper have occurred as a result of this error. The authors apologise for any inconvenience caused. In the abstract, on the sixth line, the figure 2519 should be changedto2469. Figure 1 and Tables 3 10 were updated as provided. There were also corrections to the Section 3 on page 5 In the first paragraph, (i) the first sentence beginning with A total of 3053 participants should now read: Following the removal of duplicate records, a total of 2996 participants; (ii)2519shouldbechangedto2469; (iii) 2518 should be changed to 2468; (iv) 89% should be changed to 90.4%; In the second paragraph, (i) 82.2% should be changed to 82.3%; (ii)46shouldbechangedto45; (iii) 38 should be changed to 37; (iv) 88% should be changed to 87.8%; (v) 61.1% should be changed to 60.6%; (vi) 23.4% should be changed to 23.2%; (vii) 64.0% should be changed to 39.0%. In the third paragraph, (i) 13 should be changed to 12; (ii) 45.0% should be changed to 45.4%; (iii) 61.0% should be changed to 61.7%; (iv) 76.7% should be changed to 77.1%. In the fourth paragraph,31.7% should be changed to 32.3%. Inthefifthparagraph (i) 0.97 should be changed to 0.98;

2 Neurology Research International Recruited from pilot study N=7 Recruited from main study N = 3125 Duplicates removed N = 136 Consented to participate N=2996 Commenced survey N=2554 MS diagnosis not confirmed by doctor (n =85) was excluded from analysis Answered questions about MS diagnosis N=2554 2469 respondents with confirmed MS 2233 continued to end of survey Figure 1: Participant study inclusion criteria. (ii) 1382 should be changed to 1372; (iii) 42.0% should be changed to 42.1%; (iv) 31.0% should be changed to 30.8%; (v)27.0%shouldbechangedto27.2%. Inthesixthparagraph, (ii) 63.7 should be changed to 63.5; (iii) 67.7 should be changed to 67.6. In the second paragraph, (i) 68.4% should be changed to 67.2%; (ii) 51.4% should be changed to 50.1%. (i) 81.65 should be changed to 81.7; (ii)59.2shouldbechangedto59.1; (iii) 42.3 should be changed to 42.5; (iv)77.2shouldbechangedto77.4; (v) 72.0 should be changed to 72.1; (vi) 51.2 should be changed to 51.1. Corrections to the Section 3 on page 6 In the first paragraph, (i)65.7%shouldbechangedto65.6%; Corrections to the Section 3 on page 7 In the first paragraph, (i)59.5%shouldbechangedto59.7%; (ii) 38.0% should be changed to 37.8%; (iii) 21.5% should be changed to 21.4%; (iv) 67.0% should be changed to 66.8%; (v)82.3%shouldbechangedto82.4%; (vi) 64.3% should be changed to 64.2%; (vii) 676 should be changed to 675; (viii) 30.0% should be changed to 30.1%.

Neurology Research International 3 Table 3: Characteristics of the study sample. Number (%) Characteristics (unless otherwise stated) Gender Male 407/2303 (17.7) Female 1896/2303 (82.3) Age in 2012 (years) 18 29 128/2398 (5.3) 30 39 619/2398 (25.8) 40 49 779/2398 (32.5) 50 59 634/2398 (26.4) 60 69 222/2398 (9.3) >70 16/2398 (0.7) Country of location USA 807/2469 (32.7) Australia 629/2469 (25.5) UK 417/2469 (16.9) NZ 210/2469 (8.5) Canada 105/2469 (4.3) Other 301/2469 (12.2) Country of birth USA 772/2461 (31.4) Australia 508/2461 (20.6) UK 492/2461 (20.0) NZ 172/2461 (7.0) Canada 106/2461 (4.3) Other 411/2461 (16.7) Marital status Married 1472/2431 (60.6) Single 359/2431 (14.8) Cohabitating/partnered 316/2431 (13.0) Separated/divorced 257/2431 (10.6) Widowed 27/2431 (1.1) Family status No children 766/2431 (31.5) One or more biological children 1599/2431 (65.8) Oneormorestepchildren 236/2431 (9.7) Number of children,median(iqr) 2(0 2) Employment status Employed full time 800/2459 (32.5) Employed part time 524/2459 (21.3) Stay at home parent/carer 184/2459 (7.5) Studentfulltime 60/2459 (2.4) Unemployed 196/2459 (8.0) Retiredduetoage 72/2459 (2.9) Retiredduetomedical reasonsordisability 570/2459 (23.2) Other 53/2459 (2.2) Table 3: Continued. Number (%) Characteristics (unless otherwise stated) Education status Noformalschooling 3/2455 (0.1) Primary school 52/2455 (2.1) Secondary school 549/2455 (22.4) Vocational training 395/2455 (16.1) Bachelor sdegree 888/2455 (36.2) Postgraduate degree 568/2455 (23.1) Including 52 other countries. Including 72 other countries. Including biological children and stepchildren. Collapsed from the unemployed: seeking work/not seeking work. Table 4: Diagnostic characteristics and level of disability. Number (%) Number of years since diagnosis <1 5 1098/2420 (45.4) 6 10 568/2420 (23.5) 11 15 383/2420 (15.8) 16 20 182/2420 (7.5) 21 25 96/2420 (4.0) 26 30 47/2420 (1.9) >30 46/2420 (1.9) Disability (PDDS) Normal 744/2300 (32.3) Milddisability 351/2300 (15.3) Moderatedisability 172/2300 (7.5) Gaitdisability 365/2300 (15.9) Earlycane 253/2300 (11.0) Latecane 175/2300 (7.6) Bilateral support 138/2300 (6.0) Wheelchair/scooter 99/2300 (4.3) Bedridden 3/2300 (0.1) Currently experiencing symptoms due to a recent relapse Yes 639/2394 (26.7) No 1431/2394 (59.8) Unsure 324/2394 (13.5) Definition of relapse provided to participants.

4 Neurology Research International Table 5: Diagnosed subtype of MS. Type of MS first diagnosed, number (%) Type of MS currently diagnosed, number (%) Benign Relapsing and remitting Primary progressive Secondary progressive Progressive relapsing Unsure/other 99/2418 (4.1) 1864/2418 (77.1) 151/2418 (6.2) 43/2418 (1.8) 14/2418 (0.6) 247/2418 (10.2) 100/2421 (4.1) 1493/2421 (61.7) 175/2421 (7.2) 275/2421 (11.4) 48/2421 (2.0) 330/2421 (13.6) Table 6: Relapse rate for relapsing-remitting participants. Self-diagnosed relapse rate Doctor-diagnosed relapse rate n Mean (95% CI) Median (IQR) n Mean (95% CI) Median (IQR) Number of relapses over the last 12 months 1469/1493 1.09 (1.01 1.17) 1 (0.0 2.0) 1452/1493 0.73 (0.67 0.78) 0 (0.0 1.0) Number of relapses over the last 5 years, annualised 1401/1493 0.98 (0.93 1.03) 0.67 (0.4 1.2) 1388/1493 0.66 (0.62 0.70) 0.5 (0.2 1.0) Participants with relapsing-remitting MS. Table 7: MSQOL summary scores. Summary score n (missing) Distribution (Kolmogorov) Mean (95% CI) Median (IQR) Overall quality of life subscore 2259 (210) 0.00 66.9 (66.1 67.7) 68.4 (55.0 81.7) Physical health composite 1937 (532) 0.00 59.2 (58.2 60.1) 59.1 (42.5 77.4) Mental health composite 2210 (259) 0.00 66.7 (65.8 67.6) 72.1 (51.1 84.1) Table 8: Depression and fatigue screening. Cutoff Positive, number (%, 95% CI) Negative, number (%, 95% CI) Depression screen (PHQ-2) Negative < 3; positive 3 429/2225 (19.3, 17.7 21.0) 1796/2225 (80.7, 79.0 82.3) Fatigue (FSS) mean score Negative < 4;positive 4 1402/2138 (65.6, 63.5 67.6) 736/2138 (34.4, 32.4 36.5) Table9:ComparisonofdatawithNARCOMSandMSBaseregistries. HOLISM NARCOMS [22] MSBase [45] Female (%) 82.3 74.9 71.5 Age at diagnosis (years) 37.0 (median) 36.9 (mean) 32.2 (mean) Age at symptom onset (years) 31.0 (median) 32.4 (mean) Data not provided Age at enrolment (years) 45.0 (median) 42.8 (mean) 42.7 (mean) Disease duration at enrolment (years) 6.0 (median) Data not provided 10.4 (mean)

Neurology Research International 5 Table 10: Country of residence. Country n Armenia 1 Australia 629 Austria 2 Belgium 5 Brazil 7 Bulgaria 1 Canada 105 China 1 Croatia 7 Cyprus 1 Czech Republic 2 Denmark 10 Estonia 2 Finland 4 France 11 Gibraltar 2 Guam 1 Germany 29 Greece 12 Iceland 2 India 3 Indonesia 1 Iran 1 Ireland 36 Israel 2 Italy 6 Kuwait 1 Lebanon 1 Luxembourg 1 Malta 2 Mexico 3 Namibia 1 The Netherlands 27 New Zealand 210 Norway 13 Philippines 2 Poland 3 Portugal 6 Puerto Rico 3 Qatar 1 Romania 4 Russian Federation 2 Saudi Arabia 2 Serbia 2 Singapore 2 Slovakia 4 Slovenia 2 South Africa 30 Spain 9 Table 10: Continued. Country n Sweden 16 Switzerland 8 Syria 1 Trinidad and Tobago 1 Turkey 1 United Arab Emirates 4 United Kingdom 417 United States 807

MEDIATORS of INFLAMMATION The Scientific World Journal Gastroenterology Research and Practice Diabetes Research International Endocrinology Immunology Research Disease Markers Submit your manuscripts at BioMed Research International PPAR Research Obesity Ophthalmology Evidence-Based Complementary and Alternative Medicine Stem Cells International Oncology Parkinson s Disease Computational and Mathematical Methods in Medicine AIDS Behavioural Neurology Research and Treatment Oxidative Medicine and Cellular Longevity